查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598801

子宫癌治疗和诊断市场：按癌症类型和产品分类 - 2025-2030 年全球预测

Uterine Cancer Therapeutics & Diagnostics Market by Cancer Type (Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma), Product (Diagnostics, Therapeutics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年子宫癌药物和诊断市场价值为225.5亿美元，预计2024年将达到239.5亿美元，复合年增长率为6.29%，到2030年将达到34.5亿美元，预计将达到9000万美元。

子宫癌治疗和诊断市场的范围包括子宫癌治疗和诊断的医疗产品和服务的开发、测试和分销。这包括药物、手术治疗、放射治疗、诊断测试和影像工具。由于人口老化、生活方式的改变以及早期诊断意识的增强等因素，子宫内膜癌的盛行率不断增加，因此对这个市场的需求产生了。应用范围从医院和癌症治疗中心等专业医疗机构到专注于肿瘤研究的研究机构。一系列最终用途包括医疗保健提供者、诊断实验室、专注于女性健康的製药公司等。

主要市场统计
基准年[2023] 225.5亿美元
预测年份 [2024] 239.5亿美元
预测年份 [2030] 345.9亿美元
复合年增长率（%） 6.29%

关键的成长要素包括标靶治疗、个人化医疗和非侵入性诊断技术的进步。最新的潜在机会在于人工智慧成像、分子诊断的增强以及免疫疗法和荷尔蒙疗法治疗产品平臺的扩展。解决获得医疗保健的地区差异和整合远距远端医疗服务代表着巨大的商机。然而，市场开拓面临的挑战包括高昂的药物开发成本、严格的法律规范以及低收入地区的财政限制，这些都阻碍了最先进治疗的广泛采用。

该领域的研究和开发可以集中于开发具有成本效益的筛检工具并推进遗传和生物标记研究，以更好地了解个别患者概况。还有希望研究微创手术技术和以患者为中心的癌症治疗方法，以最大限度地提高治疗后的生活品质。市场动态洞察表明，市场本质上是动态的，对改善治疗结果和以患者为中心的解决方案的需求推动了对生物技术和製药公司之间的创新和合作的强烈关注。总体而言，利用尖端研究、战略伙伴关係关係以及对患者负担和可及性的关注将决定该市场的业务成长。

市场动态：快速发展的子宫癌药物和诊断市场的关键市场洞察

由于供需之间的动态相互作用，子宫癌治疗和诊断市场正在经历转型。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 提高医生和医疗保健提供者对子宫内膜癌的认识
    • 女性健康日益重要
    • 医疗保健支出不断增加，政府对提供适当的医疗保健解决方案的兴趣日益浓厚
  • 市场限制因素
    • 治疗方法昂贵、副作用大、药物毒性严重
  • 市场机会
    • 癌症筛检和治疗方法的进步
    • 发展中国家正在针对子宫内膜癌的严重性和重要性组织各种计画。
  • 市场挑战
    • 抗癌药物临床试验成功率低

波特五力：驾驭子宫癌药物和诊断药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解子宫癌治疗和诊断药物市场的外部影响

外部宏观环境因素在塑造子宫癌治疗和诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解子宫癌治疗和诊断药物市场的竞争状况

子宫癌治疗和诊断市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

子宫癌治疗与诊断市场供应商的 FPNV 定位矩阵绩效评估

FPNV定位矩阵是评估子宫癌治疗和诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘子宫癌治疗和诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，子宫癌治疗和诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高医师和医护人员对子宫癌的认识
      • 女性健康日益重要
      • 医疗保健成本不断上升，政府越来越注重提供适当的医疗保健解决方案
    • 抑制因素
      • 治疗方法昂贵、副作用大、药物毒性严重
    • 机会
      • 癌症检测和治疗方法的进展
      • 新兴国家针对子宫癌的严重性和重要性实施了各种计划
    • 任务
      • 癌症药物临床试验的成功率较低。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按癌症类型分類的子宫癌治疗和诊断药物市场

  • 腺鳞癌
  • 子宫内膜腺癌
  • 乳头状浆液性癌
  • 子宫肉瘤

第七章子宫癌治疗与诊断药物市场：副产品

  • 诊断
    • 切片检查
    • 电脑断层扫描
    • 子宫颈扩张及刮除术
    • 子宫镜检查
    • 骨盆腔超音波检查
  • 治疗药物
    • 化疗
    • 免疫疗法
    • 放射治疗
    • 外科手术

第八章北美和南美子宫癌治疗和诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区子宫癌治疗与诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲子宫癌治疗和诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Ability Pharma
  • AstraZeneca PLC
  • BioMerieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4342CA32670E

The Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 22.55 billion in 2023, expected to reach USD 23.95 billion in 2024, and is projected to grow at a CAGR of 6.29%, to USD 34.59 billion by 2030.

The scope of the uterine cancer therapeutics and diagnostics market encompasses the development, testing, and distribution of medical products and services aimed at treating and diagnosing uterine cancer. This includes pharmaceuticals, surgical treatments, radiation therapies, diagnostic tests, and imaging tools. The necessity of this market arises from the increasing incidence rate of uterine cancer, driven by factors such as an aging population, lifestyle changes, and rising awareness about early diagnosis. The application scope extends from professional healthcare establishments like hospitals and cancer treatment centers to research institutions focused on oncological studies. The end-use scope highlights inclusion across healthcare providers, diagnostic labs, and pharmaceutical companies focusing on women's health.

KEY MARKET STATISTICS
Base Year [2023] USD 22.55 billion
Estimated Year [2024] USD 23.95 billion
Forecast Year [2030] USD 34.59 billion
CAGR (%) 6.29%

Key growth influences include advancements in targeted therapies, personalized medicine, and non-invasive diagnostic technologies. The latest potential opportunities lie in leveraging artificial intelligence for diagnostic imaging, enhancing molecular diagnostics, and expanding therapeutic product pipelines with immunotherapies and hormonal treatments. Addressing regional disparities in healthcare access and integrating telehealth services present substantive opportunities. However, market growth is challenged by high costs of drug development, stringent regulatory frameworks, and financial constraints in low-income regions, which hinder wide-scale adoption of cutting-edge treatments.

Innovation in this sector can focus on developing cost-effective screening tools and making advances in genetic and biomarker research to understand individual patient profiles better. There's promise in researching minimally invasive surgical techniques and patient-centric cancer treatment regimens that maximize quality of life post-treatment. Insight into market nature suggests it is dynamic, with a strong focus on innovation and collaboration across biotech and pharmaceutical firms, driven by a need for improved treatment outcomes and patient-centric solutions. Overall, capitalizing on cutting-edge research, strategic partnerships, and focusing on patient affordability and accessibility will define business growth in this market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Uterine Cancer Therapeutics & Diagnostics Market

The Uterine Cancer Therapeutics & Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness of uterine cancer in physicians and healthcare providers
    • Rising in importance of the women health
    • Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
  • Market Restraints
    • Expensive treatment methods along with adverse side effects and severe toxicity of the medications
  • Market Opportunities
    • Increasing advancements in the cancer screening and treatment methods
    • Developing countries organising various programmes about uterine cancer severity and importance
  • Market Challenges
    • Low success rate of cancer drug clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Uterine Cancer Therapeutics & Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Uterine Cancer Therapeutics & Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Uterine Cancer Therapeutics & Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Uterine Cancer Therapeutics & Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Uterine Cancer Therapeutics & Diagnostics Market

A detailed market share analysis in the Uterine Cancer Therapeutics & Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Uterine Cancer Therapeutics & Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Uterine Cancer Therapeutics & Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Uterine Cancer Therapeutics & Diagnostics Market

A strategic analysis of the Uterine Cancer Therapeutics & Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Uterine Cancer Therapeutics & Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ability Pharma, AstraZeneca PLC, BioMerieux S.A., Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Uterine Cancer Therapeutics & Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma.
  • Based on Product, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biopsy, CT Scan, Dilation & Curettage, Hysteroscopy, and Pelvic Ultrasound. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness of uterine cancer in physicians and healthcare providers
      • 5.1.1.2. Rising in importance of the women health
      • 5.1.1.3. Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive treatment methods along with adverse side effects and severe toxicity of the medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing advancements in the cancer screening and treatment methods
      • 5.1.3.2. Developing countries organising various programmes about uterine cancer severity and importance
    • 5.1.4. Challenges
      • 5.1.4.1. Low success rate of cancer drug clinical trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Uterine Cancer Therapeutics & Diagnostics Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Adenosquamous Carcinoma
  • 6.3. Endometrial Adenocarcinoma
  • 6.4. Papillary Serous Carcinoma
  • 6.5. Uterine Sarcoma

7. Uterine Cancer Therapeutics & Diagnostics Market, by Product

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Biopsy
    • 7.2.2. CT Scan
    • 7.2.3. Dilation & Curettage
    • 7.2.4. Hysteroscopy
    • 7.2.5. Pelvic Ultrasound
  • 7.3. Therapeutics
    • 7.3.1. Chemotherapy
    • 7.3.2. Immunotherapy
    • 7.3.3. Radiation Therapy
    • 7.3.4. Surgery

8. Americas Uterine Cancer Therapeutics & Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Ability Pharma
  • 4. AstraZeneca PLC
  • 5. BioMerieux S.A.
  • 6. Danaher Corporation
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Siemens Healthineers AG
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ADENOSQUAMOUS CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ENDOMETRIAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PAPILLARY SEROUS CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY UTERINE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DILATION & CURETTAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PELVIC ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023